Jury member of Biotech Investor Panel

Bram Vanparys | Partner, Gimv

Bram Vanparys joined Gimv in 2018. Bram has over 10 years of international venture capital experience, most recently at Merck Ventures in Amsterdam. He has a successful track record in Life Science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe and Israel, including arGEN-X (ARGX:EBR), Multiplicom (acquired by Agilent), Cartagenia (acquired by Agilent), Q-Biologicals (acquired by Amatsigroup, now Eurofins), Calypso Biotech and iOmx. Today, Bram acts as a board member for portfolio companies ImCheck Therapeutics (France), iSTAR Medical (Belgium), Kinaset Therapeutics (US) and Topas Therapeutics (Germany). Bram is trained as a PhD in biotechnology (University of Ghent, Belgium) and has an executive MBA from Vlerick Business School (Belgium).

About Gimv

Gimv is a European investment company, listed on Euronext Brussels, with 40 years' experience in private equity and venture capital. The company currently has a portfolio of EUR 1.1 billion of investments in around 50 portfolio companies, with a combined turnover of EUR 2.5 billion and 14,000 employees. As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial, innovative companies with high growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are Connected Consumer, Health & Care, Smart Industries & Sustainable Cities. Each platform works with an experienced team across Gimv’s home markets of Benelux, France and DACH, supported by an extended international network of experts.